Petros Pharmaceuticals, Inc. (NASDAQ:PTPI – Get Free Report)’s stock price shot up 8.7% during trading on Tuesday . The stock traded as high as $0.11 and last traded at $0.10. 32,615,548 shares changed hands during trading, an increase of 1,470% from the average session volume of 2,076,846 shares. The stock had previously closed at $0.09.
Petros Pharmaceuticals Trading Down 7.6 %
The firm’s 50 day moving average is $0.24 and its 200 day moving average is $0.30. The company has a market cap of $960,983.10, a PE ratio of -0.02 and a beta of 2.04. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.85 and a quick ratio of 0.74.
Petros Pharmaceuticals Company Profile
Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
See Also
- Five stocks we like better than Petros Pharmaceuticals
- Growth Stocks: What They Are, What They Are Not
- 3 Undervalued Stocks You Can Buy at a Discount Now
- 3 Tickers Leading a Meme Stock Revival
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
